Tscan Therapeutics Inc (TCRX) - Total Liabilities
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has total liabilities worth $105.67 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TCRX cash flow conversion to assess how effectively this company generates cash.
Tscan Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Tscan Therapeutics Inc (TCRX) asset resilience to evaluate the company's liquid asset resilience ratio.
Tscan Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tscan Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DCC plc
LSE:DCC
|
UK | GBX5.52 Billion |
|
Fairvest Ltd
JSE:FTA
|
South Africa | ZAC4.72 Billion |
|
Spruce Power Holding Corp
NYSE:SPRU
|
USA | $716.02 Million |
|
Nh Prime Reit Co Ltd
KO:338100
|
Korea | ₩2.03 Billion |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
India | Rs17.64 Billion |
|
PBG S.A
SA:PTBL3
|
Brazil | R$3.37 Billion |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
India | Rs26.68 Billion |
|
iFabric Corp
TO:IFA
|
Canada | CA$9.26 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Tscan Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TCRX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tscan Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Tscan Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $105.67 Million | -18.81% |
| 2024-12-31 | $130.15 Million | +7.31% |
| 2023-12-31 | $121.28 Million | +21.70% |
| 2022-12-31 | $99.66 Million | +264.66% |
| 2021-12-31 | $27.33 Million | -70.36% |
| 2020-12-31 | $92.20 Million | +1247.95% |
| 2019-12-31 | $6.84 Million | -- |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more